GlassScriptPhysician profile
Zachary S Mccarty
NPI 1912011131
$3,835.77
in general payments reported to CMS, 2019-2025
27 companies · $466 in 2025
The $466 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $244 · 2021: $489 · 2022: $532 · 2023: $550 · 2024: $915 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $887.98 | 2019-2025 | Clareon, Total30, Dailies Total1 |
| Bausch & Lomb Americas INC. | $472.66 | 2022-2024 | Infuse, Vyzulta, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $395.24 | 2019-2025 | Tecnis Iol |
| Coopervision INC. | $340.36 | 2019-2023 | Misight Contact Lens |
| Glaukos Corporation | $248.32 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $202.03 | 2021-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $148.08 | 2019-2021 | |
| Biotissue Holdings INC. | $128.64 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $112.45 | 2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $107.35 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.93 | 2019 | |
| Abbvie INC. | $82.44 | 2024-2025 | |
| Allergan, INC. | $80.82 | 2020-2022 | |
| Dompe US, INC. | $67.85 | 2019-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $66.74 | 2021-2023 | Eylea |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $58.11 | 2024 | Xdemvy |
| Mallinckrodt Enterprises LLC | $54.14 | 2019 | |
| Horizon Therapeutics Plc | $43.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $42.80 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $42.05 | 2022 | |
| Abbott Laboratories | $38.13 | 2025 | Cardiomems |
| Rxsight INC | $24.42 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Alimera Sciences, INC. | $21.62 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Alcon Research LLC | $18.31 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Eyevance Pharmaceuticals LLC | $15.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.